Physician profile

Robert C Brown

Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) · Mobile, AL

NPI 1932223526

$8,304.57

in general payments reported to CMS, 2019-2025

44 companies · $1,342 in 2025

The $1,342 reported for 2025 was more than what 75% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,268.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Axonics, INC. $1,860.55 2020-2024 Axonics
Intuitive Surgical, INC. $1,767.23 2019-2024
Abbvie INC. $1,001.80 2019-2025 Botox
Astellas Pharma US INC $542.82 2019-2023 Veozah, Myrbetriq
Boston Scientific Corporation $481.23 2019-2025 Axonics, Spaceoar Vue System - 10ml
Sumitomo Pharma America, INC. $455.00 2023-2025 Gemtesa, Orgovyx
Therapeuticsmd, INC. $268.63 2019-2022
Pfizer INC. $251.65 2019-2022
Coloplast Corp $227.45 2019-2025
Allergan, INC. $128.12 2020-2022
Immunitybio, INC. $104.18 2025
Procept Biorobotics Corporation $88.05 2024 Aquabeam System
Scynexis, INC. $86.27 2022
Janssen Biotech, INC. $83.83 2025 Erleada
Millicent US INC $75.16 2019-2025 Intrarosa, Femring
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $72.10 2023-2025 Nuro, Interstim
Urovant Sciences INC $69.39 2022
Ascend Therapeutics US, LLC $59.04 2022-2023
Applied Medical Resources Corporation $58.92 2021
Duchesnay USA Incorporated $55.75 2019
Antares Pharma, INC. $51.55 2021-2022
Mayne Pharma Commercial LLC $41.42 2023
Bioprotect Medical, INC. $39.07 2025 Bioprotect Balloon Implant System
Exeltis, USA INC. $38.84 2019
C. R. Bard, INC. & Subsidiaries $32.86 2025 Magic3 Go Intermittent Urinary Catheter
Baxter Healthcare $30.52 2021
Urogen Pharma, INC. $29.64 2025
Dilon Technologies, INC. $25.76 2025 Hemoblast Bellows
Mycovia Pharmaceuticals, INC. $25.57 2022
Amag Pharmaceuticals, INC. $22.16 2019
Inspire Medical Systems, INC. $21.98 2024 Inspire
180 Medical, INC. $21.70 2025 Gentlecath Glide
Myriad Genetic Laboratories, INC. $18.53 2024 Prolaris
Vertex Pharmaceuticals Incorporated $18.03 2025
Novartis Pharmaceuticals Corporation $17.85 2025
Meditrina $16.91 2022
Tolmar, INC. $16.38 2025 Eligard, Jatenzo
Daiichi Sankyo INC. $15.69 2019
Vertical Pharmaceuticals, LLC $15.63 2020
Lsi Solutions INC $14.46 2024 Jnw Urtrac, Ti-Knot, Running Device
Caldera Medical, INC $13.95 2023 Desara
Ambu INC. $13.52 2025
Olympus America INC. $13.04 2020
Ethicon US, LLC $12.34 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert C Brown

$8,304.57

in general payments reported 2019-2025

Years
2019-2025
Top company
Axonics, INC.
Context
The $1,342 reported for 2025 was more than what 75% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).

https://glasscript.com/doctor/87989/robert-c-brown

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.